Mn Services Vermogensbeheer B.V. Purchases 12,767 Shares of Becton, Dickinson and Company $BDX

Mn Services Vermogensbeheer B.V. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 15.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,867 shares of the medical instruments supplier’s stock after buying an additional 12,767 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Becton, Dickinson and Company were worth $17,160,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently bought and sold shares of BDX. TD Waterhouse Canada Inc. grew its holdings in shares of Becton, Dickinson and Company by 17.1% in the second quarter. TD Waterhouse Canada Inc. now owns 96,211 shares of the medical instruments supplier’s stock valued at $14,715,000 after purchasing an additional 14,077 shares in the last quarter. Northside Capital Management LLC lifted its holdings in Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after buying an additional 9,494 shares in the last quarter. NewEdge Advisors LLC boosted its position in Becton, Dickinson and Company by 35.0% in the 1st quarter. NewEdge Advisors LLC now owns 44,032 shares of the medical instruments supplier’s stock valued at $6,923,000 after buying an additional 11,414 shares during the period. Beverly Hills Private Wealth LLC acquired a new position in shares of Becton, Dickinson and Company in the second quarter worth $3,353,000. Finally, Wealthfront Advisers LLC purchased a new stake in shares of Becton, Dickinson and Company during the second quarter worth $2,567,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.5%

NYSE:BDX opened at $183.69 on Friday. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $193.07. The stock has a market cap of $50.61 billion, a P/E ratio of 55.33, a P/E/G ratio of 12.32 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The stock has a 50-day simple moving average of $182.33 and a 200-day simple moving average of $162.52.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The business had revenue of $4.98 billion for the quarter, compared to analyst estimates of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. The business’s quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter last year, the company earned $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, analysts anticipate that Becton, Dickinson and Company will post 12.67 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th were given a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a dividend yield of 2.3%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company’s payout ratio is currently 126.51%.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Royal Bank Of Canada increased their price target on Becton, Dickinson and Company from $180.00 to $190.00 and gave the company a “sector perform” rating in a research report on Thursday, August 13th. Jefferies Financial Group reiterated a “buy” rating and issued a $210.00 price objective on shares of Becton, Dickinson and Company in a research note on Thursday, August 6th. TD Cowen raised their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Finally, Wells Fargo & Company lifted their price target on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Seven investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $185.07.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael Feld sold 165 shares of the firm’s stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the transaction, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the business’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 6,906 shares of company stock valued at $1,265,855 in the last ninety days. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD’s Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.